Table 4 Treatment characteristics by line of treatment
From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Treatment | First-line | Second-line | Third-line | Fourth-line |
|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | |
N | 168 | 79 | 25 | 10 |
TKI | 137 (81.5) | 24 (30.4) | 6 (24.0) | 5 (50.0) |
Gefitinib | 114 (83.2) | 4 (16.7) | 1 (16.7) | 0 (0.0) |
Erlotinib | 23 (16.8) | 20 (83.3) | 4 (66.7) | 0 (0.0) |
Afatinib | 0 (0.0) | 0 (0.0) | 1 (16.7) | 5 (100) |
CT | 31 (18.5) | 43 (54.4) | 14 (56.0) | 4 (40.0) |
Doublet | 24 (77.4) | 26 (60.5) | 5 (35.7) | 1 (25.0) |
Monochemotherapy | 4 (12.9) | 16 (37.2) | 8 (57.1) | 2 (50.0) |
Triplet | 3 (9.7) | 1 (2.3) | 1 (7.1) | 1 (25.0) |
CT + maintenance TKI | 8 (4.8) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
CT + maintenance CT | 2 (1.2) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
Other | 0 (0.0) | 1 (1.3) | 2 (8.0) | 0 (0.0) |